ABIVAX (EPA:ABVX) | Finanzwire

PRESS RELEASE

published on 02/02/2024 at 08:30, 2 years 3 months ago

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Abivax updates obefazimod Phase 2b clinical program in Crohn’s disease following FDA feedback. Trial design modification to align with FDA recommendations. Patient enrollment to start in Q3 2024

Abivax Obefazimod Crohn’s Disease Phase 2b Clinical Trial FDA Feedback
PRESS RELEASE

published on 01/24/2024 at 08:30, 2 years 3 months ago

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
Abivax, a clinical-stage biotechnology company, will host a virtual KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with ulcerative colitis on February 6, 2024. The event will feature discussions on the unmet medical need, current treatment landscape, and ongoing clinical development plans for obefazimod. The key speakers at the event will be Marla Dubinsky, MD, and Parambir Dulai, MD, who are both consultants for Abivax and members of the Steering Committee for the IBD Program.

Abivax Obefazimod Ulcerative Colitis Clinical Development KOL Investor Event
PRESS RELEASE

published on 01/22/2024 at 08:30, 2 years 3 months ago

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
Abivax, a clinical-stage biotechnology company, provides its 2024 strategic outlook and key milestones, including the expected data read-outs and trial results for its lead drug candidate obefazimod in the treatment of ulcerative colitis and Crohn’s disease. The company also outlines its financial update and objectives for strengthening its product pipeline. Learn more about Abivax's priorities and milestones for 2024.

Abivax Obefazimod Ulcerative Colitis Crohn’s Disease Clinical Trials
PRESS RELEASE

published on 10/24/2023 at 22:05, 2 years 6 months ago

Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE

published on 10/20/2023 at 16:00, 2 years 6 months ago

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris
PRESS RELEASE

published on 10/20/2023 at 15:45, 2 years 6 months ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
PRESS RELEASE

published on 10/20/2023 at 15:00, 2 years 6 months ago

Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market
PRESS RELEASE

published on 10/20/2023 at 08:45, 2 years 6 months ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
PRESS RELEASE

published on 10/19/2023 at 00:00, 2 years 6 months ago

Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range
PRESS RELEASE

published on 10/16/2023 at 17:40, 2 years 6 months ago

Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing

Published on 05/02/2026 at 21:00, 19 hours 57 minutes ago

GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 1 day 15 hours ago

Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 1 day 16 hours ago

CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/02/2026 at 00:00, 1 day 16 hours ago

Redwood AI Announces Enhanced AI Models, Increasing Evaluated Chemical Reactions Following Preliminary Results from UBC Collaboration
Published on 05/02/2026 at 00:00, 1 day 16 hours ago

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

View all ACCESSWIRE

Published on 05/03/2026 at 04:45, 12 hours 11 minutes ago

GWM Unveils World-Class Safety & Testing Facilities: Safety Built on Data, Not Hype
Published on 05/02/2026 at 15:35, 1 day 1 hour ago

Ecuador's banana sector renews labor agreement, with jobs meeting global standards
Published on 05/01/2026 at 19:23, 1 day 21 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 05/01/2026 at 18:40, 1 day 22 hours ago

Holding(s) in Company
Published on 05/01/2026 at 17:47, 1 day 23 hours ago

Key Figures 30.04.2026

View all EQS

Published on 04/30/2026 at 20:00, 2 days 20 hours ago

AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 2 days 21 hours ago

AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 2 days 21 hours ago

Capital increase through exercise of subscription rights
Published on 04/30/2026 at 18:10, 2 days 22 hours ago

Minutes of the Combined General Meeting held on April 30, 2026
Published on 04/30/2026 at 18:00, 2 days 22 hours ago

TF1 Q1 2026 results - Press release

View all LES ECHOS COMFI WIRE

News